Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY20 results · Jul–Sep 2019
Bliss GVS Pharma reported revenue from operations of ₹210.12 crore (down 8.0% from Q2 FY19) and net profit of ₹30.86 crore (down 25.9% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 210.12 | 228.43 | −8.0% | 211.53 | −0.7% |
| Other income | 12.90 | 24.87 | −48.2% | 2.11 | +511.1% |
| Total income | 223.02 | 253.31 | −12.0% | 213.64 | +4.4% |
| Profit before tax | 33.81 | 62.79 | −46.2% | 47.41 | −28.7% |
| Net profit for the period | 30.86 | 41.67 | −25.9% | 33.37 | −7.5% |
| Attributable to shareholders of the company | 30.98 | 41.46 | −25.3% | 33.79 | −8.3% |
| EPS, basic (₹) | 3.00 | 4.02 | −25.4% | 3.28 | −8.5% |
| Net margin (%) | 14.7 | 18.2 | 15.8 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 104.00 | 119.97 | −13.3% | 115.16 | −9.7% |
| Other income | 12.29 | 24.01 | −48.8% | 1.79 | +585.5% |
| Total income | 116.30 | 143.98 | −19.2% | 116.95 | −0.6% |
| Profit before tax | 30.50 | 49.20 | −38.0% | 36.11 | −15.5% |
| Net profit for the period | 28.44 | 31.05 | −8.4% | 23.92 | +18.9% |
| EPS, basic (₹) | 2.76 | 3.01 | −8.3% | 2.32 | +19.0% |
| Net margin (%) | 27.3 | 25.9 | 20.8 |
Consolidated
- Filed with BSE
- 13 Nov 2019, 12:10 IST
- Board meeting
- 11 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2019, 12:10 IST
- Board meeting
- 11 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE